Repurposing of investigational cancer drugs: Early phase discovery of dengue virus NS2B/NS3 protease inhibitors.
Saleem HN, Kousar S, Jiskani AH, Sohail I, Faisal A, Saeed M.
Arch Pharm (Weinheim) · journal article · DOI 10.1002/ardp.202300292 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för TW-37. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
25 träffarEpigenetic alternations and targeted therapy in intrauterine adhesion: A comparative study.
Gao L, Liang E, Zhang D, Zhang Y, Zhang X, Jiang G, Chen S, Li N, Wang X, Shen Y.
Genomics · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ygeno.2023.110673Exploring the robustness of DNA nanotubes framework for anticancer theranostics toward the 2D/3D clusters of hypopharyngeal respiratory tumor cells.
Baig MMFA, Ma J, Gao X, Khan MA, Ali A, Farid A, Zia AW, Noreen S, Wu H.
Int J Biol Macromol · journal article · DOI 10.1016/j.ijbiomac.2023.123988KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease.
Mori Y, Ajay AK, Chang JH, Mou S, Zhao H, Kishi S, Li J, Brooks CR, Xiao S, Woo HM, Sabbisetti VS, Palmer SC, Galichon P, Li L, Henderson JM, Kuchroo VK, Hawkins J, Ichimura T, Bonventre JV.
Cell Metab · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.cmet.2021.04.004Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells.
Yu R, Lu Y, Yu R, Xie J, Zhou S.
Cancer Manag Res · research-article; journal article · DOI 10.2147/cmar.s265788Cryptotanshinone chemosensitivity potentiation by TW-37 in human oral cancer cell lines by targeting STAT3-Mcl-1 signaling.
Yang IH, Hong SH, Jung M, Ahn CH, Yoon HJ, Hong SD, Cho SD, Shin JA.
Cancer Cell Int · research-article; journal article · DOI 10.1186/s12935-020-01495-2Sensitive fluorogenic substrates for sirtuin deacylase inhibitor discovery.
Yang LL, Wang HL, Yan YH, Liu S, Yu ZJ, Huang MY, Luo Y, Zheng X, Yu Y, Li GB.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2020.112201Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets.
Wei H, Harper MT.
Platelets · journal article · DOI 10.1080/09537104.2020.1724276Antitumor effect of TW-37, a BH3 mimetic in human oral cancer.
Ahn CH, Lee WW, Jung YC, Shin JA, Hong KO, Choi S, Swarup N, Kim J, Ahn MH, Jung M, Cho SD, Jin B.
Lab Anim Res · research-article; journal article · DOI 10.1186/s42826-019-0028-7Heme Oxygenase-1 is a Key Molecule Underlying Differential Response of TW-37-Induced Apoptosis in Human Mucoepidermoid Carcinoma Cells.
Yang IH, Ahn CH, Cho NP, Jin B, Lee W, Jung YC, Hong SD, Shin JA, Cho SD.
Molecules · research-article; journal article · DOI 10.3390/molecules24091700The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines.
Klenke S, Akdeli N, Stelmach P, Heukamp L, Schulte JH, Bachmann HS.
BMC Cancer · research-article; journal article · DOI 10.1186/s12885-019-5439-1TW37 enhances the pro-apoptosis and anti-migration ability of gefitinib in Non-Small Cell Lung Cancer.
Chen X, Mao G, Chen H, Liu S, Wang S, Li X, Ye Y, Wu H, Liu J.
Cell Mol Biol (Noisy-le-grand) · journal article · DOI 10.14715/cmb/2018.64.4.2Effect of TW37 on the growth of H1975 EGFR‑TKI‑resistant lung cancer cells and its underlying mechanisms.
Liu J, Yao X, Wu D, Ye Y, Wu Q, Liu S, Wu H.
Mol Med Rep · journal article · DOI 10.3892/mmr.2017.8181The preclinical analysis of TW-37 as a potential anti-colorectal cancer cell agent.
Lei S, Ding Y, Fu Y, Wu S, Xie X, Wang C, Liang H.
PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0184501Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.
Lu Y, Huang H, Yang H, Chen D, Wu S, Jiang Z, Wang R.
Cell Cycle · report; journal article · DOI 10.1080/15384101.2017.1329066Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37.
Green MM, Shekhar TM, Hawkins CJ.
Data Brief · other; journal article · DOI 10.1016/j.dib.2016.01.013Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells.
Wang H, Zhang Z, Wei X, Dai R.
J Ovarian Res · research-article; journal article · DOI 10.1186/s13048-015-0130-xEvaluation and critical assessment of putative MCL-1 inhibitors.
Varadarajan S, Vogler M, Butterworth M, Dinsdale D, Walensky LD, Cohen GM.
Cell Death Differ · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/cdd.2013.79Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation.
Zeitlin BD, Spalding AC, Campos MS, Ashimori N, Dong Z, Wang S, Lawrence TS, Nör JE.
Int J Radiat Oncol Biol Phys · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ijrobp.2010.04.024TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis.
Ashimori N, Zeitlin BD, Zhang Z, Warner K, Turkienicz IM, Spalding AC, Teknos TN, Wang S, Nör JE.
Mol Cancer Ther · research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-08-1078TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway.
Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, Mohammad RM.
Cancer Res · research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-08-3060SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status.
Al-Katib AM, Sun Y, Goustin AS, Azmi AS, Chen B, Aboukameel A, Mohammad RM.
J Hematol Oncol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1186/1756-8722-2-8TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer.
Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee S, Kong D, Wang S, Sarkar FH, Mohammad RM.
Int J Cancer · retracted publication; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1002/ijc.23610Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A.
Clin Cancer Res · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-06-1574Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2.
Zeitlin BD, Joo E, Dong Z, Warner K, Wang G, Nikolovska-Coleska Z, Wang S, Nör JE.
Cancer Res · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-05-3691